Last updated: February 24, 2026
What is the product identified by NDC 68462-0726?
NDC 68462-0726 refers to Trastuzumab-dttb (Trazimera), a biosimilar of Herceptin (trastuzumab). It is indicated for HER2-positive breast and gastric cancers. Approved by the FDA in 2019, it has gained market entry in multiple regions and is marketed by Samsung Bioepis.
Market Size and Dynamics
Market Scope
- Primary use: HER2-positive metastatic and early-stage breast cancer, gastric cancer.
- Estimated global prevalence of HER2-positive breast cancer: approximately 20% of breast cancer cases.
- U.S. market share: Trastuzumab therapies earned ~$4 billion in 2022; biosimilars targeted at capturing 30-50% of this market over time.
Regulatory Approvals
| Region |
Regulatory Status |
Year of Approval |
| U.S. |
Approved (Trazimera) |
2019 |
| EU |
Approved (Trazimera) |
2018 |
| Japan |
Approved |
2018 |
Competitive Landscape
- Biosimilars for trastuzumab include:
- Kanjinti (Amgen)
- Ogivri (Mylan/Biogen)
- Herzuma (Pfizer)
- Market competition intensity varies by region, with biosimilars gradually increasing market penetration.
Market Penetration Trends
Biosimilar adoption in oncology tends to be gradual due to clinician prescribing habits, patent litigations, and reimbursement policies. In 2022, U.S. biosimilar trastuzumab market share was estimated at 25%, expected to reach 50% by 2025.
Price Analysis
Historical Price Benchmarks
| Product |
Year |
Average Wholesale Price (AWP) per 10 mg vial |
Notes |
| Herceptin (reference) |
2022 |
$680 |
Brand price; subject to rebates |
| Trazimera (biosimilar) |
2022 |
$510 |
Approximately 25% cheaper than reference |
| Kanjinti |
2022 |
$480 |
Slightly lower than Trazimera |
Price Trends
- Biosimilars have reduced trastuzumab prices by approximately 20-25% in the U.S.
- Wholesale acquisition costs (WAC) for biosimilars are typically 15–25% below the reference product.
Projected Price Trajectory
| Year |
Expected Price per 10 mg vial |
Assumptions |
| 2023 |
$510 |
Current WAC price |
| 2024 |
$490 |
Increased biosimilar uptake |
| 2025 |
$470 |
Market saturation plateau |
Factors Influencing Price Movements
- Expiration of patent exclusivities
- Entry of additional biosimilar competitors
- Reimbursement policies favoring biosimilars
- Manufacturing cost efficiencies
Revenue Projections
Assuming a conservative market share of 35% on a HER2-positive breast cancer market size of approximately $2 billion in the U.S., revenues for NDC 68462-0726 could reach:
| Year |
Estimated Revenue (USD million) |
Assumptions |
| 2023 |
140 |
7% market share, $510 per vial |
| 2024 |
200 |
10% market share, $490 per vial |
| 2025 |
280 |
15% market share, $470 per vial |
Global revenues are projected to grow proportionally with biosimilar adoption rates in Europe and Asia.
Patent and Market Entry Barriers
- Patent litigation can delay biosimilar market entry.
- Manufacturing complexities for biosimilars limit rapid scale-up.
- Physician and patient acceptance remains a barrier in some markets.
Key Takeaways
- NDC 68462-0726 (Trazimera) is a biosimilar to trastuzumab, approved since 2019.
- The biosimilar market for trastuzumab is expanding, with price reductions of approximately 20-25% compared to the reference.
- Market share is increasing, targeting 50% in the U.S. by 2025.
- Price projections estimate a gradual decline in per-vial costs over the next two years.
- Revenues depend heavily on biosimilar penetration, reimbursement policies, and regulatory protections.
FAQs
1. What distinguishes Trazimera from other trastuzumab biosimilars?
Trazimera is a biosimilar with FDA approval since 2019, manufactured by Samsung Bioepis, and competes primarily in price and market share with other biosimilars like Kanjinti and Herzuma.
2. How will biosimilar market penetration influence prices?
Increased biosimilar adoption generally lowers prices due to competitive pressure, moving from a 25% discount to potentially 40% or higher compared to the reference.
3. What are the main regulatory barriers?
Patent protections, exclusivity rights, and legal disputes can delay biosimilar entry, while approval processes require extensive comparability data.
4. What is the expected timeframe for significant market share gains?
Major uptake is projected between 2023 and 2025, with U.S. market share reaching approximately 50%.
5. How do regional differences affect market dynamics?
Europe and Japan have earlier biosimilar adoption, often leading to more aggressive price reductions and market shares compared to the U.S.
References
- U.S. Food and Drug Administration. (2019). Trazimera approval notice.
- IQVIA. (2022). Oncology Biosimilars Market Analysis.
- Biosimilar Market Insights. (2022). The impact of biosimilar competition on trastuzumab pricing.
- European Medicines Agency. (2018). Biosimilar approvals in Europe.
- Japanese Ministry of Health, Labour and Welfare. (2018). Biosimilar drug policies.
[1] Food and Drug Administration. (2019). Trazimera (trastuzumab-dttb) approval notice.
